April A N Rose
Overview
Explore the profile of April A N Rose including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos A, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400199.
PMID: 39869838
Purpose: MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy...
2.
Lazaratos A, Dankner M, Hamouda A, Labidi S, Cohen V, Panasci L, et al.
Curr Oncol
. 2025 Jan;
32(1.
PMID: 39851917
Background: Trastuzumab deruxtecan (TDXd) is an antibody-drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer....
3.
Elkholi I, Rose A, Aguirre-Ghiso J, Cote J
Cancer Cell
. 2024 Jun;
42(7):1147-1151.
PMID: 38906154
Clinical practice and clinical research heavily rely on primary tumors, circulating tumor DNA, and/or overt metastases as sources of material for predicting or investigating breast cancer metastatic relapses. However, these...
4.
Dankner M, Maxwell J, Rose A
Transl Lung Cancer Res
. 2024 May;
13(4):930-935.
PMID: 38736490
No abstract available.
5.
Liu R, Ferrario C, Fallah P, Rose A, Labidi S, Mamo A, et al.
Nucl Med Commun
. 2024 May;
45(8):683-689.
PMID: 38726601
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains uniformly lethal. Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein overexpressed in prostate cancer. 131 I-PSMA-1095 (also known as 131 I-MIP-1095) is...
6.
Bian D, Lazaratos A, Maritan S, Quaiattini A, Zeng Z, Zhu Z, et al.
Heliyon
. 2024 May;
10(9):e29668.
PMID: 38698967
Purpose: Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). In patients with NSCLC LM harboring epidermal growth factor receptor () mutations, osimertinib is favored over...
7.
Labidi S, Meti N, Barua R, Li M, Riromar J, Jiang D, et al.
BMJ Open
. 2024 Mar;
14(3):e081480.
PMID: 38553056
Objectives: Immune checkpoint inhibitors (ICIs) are indicated for metastatic urothelial cancer (mUC), but predictive and prognostic factors are lacking. We investigated clinical variables associated with ICI outcomes. Methods: We performed...
8.
Kazandjian S, Rousselle E, Dankner M, Cescon D, Spreafico A, Ma K, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38275886
Background: BRAF mutations are classified into four molecularly distinct groups, and Class 1 (V600) mutant tumors are treated with targeted therapies. Effective treatment has not been established for Class 2/3...
9.
Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose A
Nat Rev Cancer
. 2024 Jan;
24(2):105-122.
PMID: 38195917
The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF, drives tumour progression and drug resistance in...
10.
Vilbert M, Koch E, Rose A, Laister R, Gray D, Sotov V, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509369
Cutaneous melanoma (CM) patients respond better to immune checkpoint inhibitors (ICI) than mucosal and uveal melanoma patients (MM/UM). Aiming to explore these differences and understand the distinct response to ICI,...